Intrinsiqq
AnaptysBio Inc. logo

AnaptysBio Inc. Quality Score

ANAB

Compare
Quality20

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-53.8x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-11.4x

Negative FCF, no valuation support

Not enough quarterly data
for a 1-year trend

Revenue Growth
0/100
-38.8%

Below 2%, essentially flat

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
100/100
-29.9%

Shrinking >2%, active buybacks

Margin Trend
0/100
-926.4pp

Contracted >2pp, margin pressure

Capital Structure
100/100
-$286M

Net cash position, no leverage concern

2020
$394M
$342000
2021
$548M
$21.0M
2022
$441M
$19.0M
2023
$391M
$18.0M
TTM
$286M
$13613
CashDebt
Return on Capital
0/100
-67.0%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

AnaptysBio (ANAB) quality: score, margins and returns

AnaptysBio (ANAB) scores 20/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 6 metrics each scored 0 to 100. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is AnaptysBio (ANAB) a high-quality business?+

AnaptysBio scores 20 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does AnaptysBio's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from ANAB's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where AnaptysBio scores well and where it falls behind.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 12 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 12 Nov 2026. How this is calculated.

Fiscal year ends Jun. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ANAB

CompareIntrinsic value
EVFMEvofem Biosciences Inc.
$1.00+0.00%15
KPRXKiora Pharmaceuticals Inc.
$0.72-12.30%10
CELUCelularity Inc.
$0.46-1.88%0
EMMAEmmaus Life Sciences, Inc.
$0.04+52.17%21
SCYXScynexis, Inc.
$2.38-8.64%40
SLGLSol-Gel Technologies Ltd.
$55.17+2.02%65
QUREuniQure N.V.
$19.35-4.35%10
CTMXCytomX Therapeutics Inc.
$2.03-0.98%10

Held by ETFs

ANAB is in 54 US ETFs. The largest of them, with ANAB's weight in each:

Spot a number that looks wrong? Check it in ANAB's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ANAB

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.